U.S. markets closed

89bio, Inc. (ETNB)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.19+0.45 (+9.49%)
At close: 04:00PM EDT
5.37 +0.18 (+3.47%)
After hours: 05:04PM EDT

89bio, Inc.

142 Sansome Street
2nd Floor
San Francisco, CA 94104
United States
415 432 9270

Full Time Employees41

Key Executives

NameTitlePayExercisedYear Born
Mr. Rohan PalekarCEO & Director829.41kN/A1966
Mr. Quoc Le-NguyenChief Technical Operations Officer & Head of Quality571.12kN/A1968
Dr. Harry Mansbach M.D.Chief Medical Officer603.22kN/A1965
Mr. Ryan Stephen MartinsChief Financial OfficerN/AN/A1978
Mr. Shiva K. NatarajanSr. VP of Fin. & Principal Accounting OfficerN/AN/A1966
Ms. Melissa AbelSr. VP of Commercial Strategy & CommunicationsN/AN/AN/A
Ms. Amanda HillVP of People & CultureN/AN/AN/A
Ms. Yun BaiVP & Head of CMCN/AN/AN/A
Mr. Paul ShinSr. VP of R&D OperationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Corporate Governance

89bio, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 8. The pillar scores are Audit: 9; Board: 7; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.